Roche terminates licensing agreement with AC Immune
January 22, 2024 at 10:37 am EST
Share
AC Immune announced on Monday that Switzerland's Roche had terminated its licensing agreement with the biotech company to co-develop a new treatment for Alzheimer's disease.
The Lausanne-based, Nasdaq-listed company said the healthcare giant's decision would not prevent it from pursuing phase 2 development of its immunotherapies, for which it will take over full rights.
Following its $50 million capital increase completed last month, AC Immune believes it is sufficiently funded to continue its activities until 2026.
The partnership with Roche concerned crenezumab, a humanized monoclonal antibody designed to slow the progression of Alzheimer's disease by neutralizing neurotoxic beta-amyloid oligomers.
It also concerned semorinemab, another 'anti-Tau' antibody targeting the N-terminus of the Tau protein, designed to narrow the space between neurons.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.